Can a Blood Test Help Assess ADHD? microRNA Evidence, Limitations and Cost

After years of missed deadlines, lost belongings or disagreements over a child’s behavior, it is understandable to want a clear test result. A blood sample sounds more definite than another questionnaire. The useful question is what that result can actually add to an assessment.

Blood-based microRNA tests are now available as an adjunct to ADHD assessment. Before deciding whether to have one, it helps to understand what the result can tell you, beyond a single accuracy figure.

There is currently no single test that can diagnose ADHD on its own. Laboratory information needs to be interpreted alongside a person’s history, symptoms and daily functioning.^[6]

How is ADHD assessed, and where could a blood test fit?

Clinical assessment asks whether attention, activity and impulse-control difficulties form a persistent pattern, how early that pattern began, where it appears and what it costs the person in everyday life. For children, observations from caregivers and teachers help establish what happens in different environments. Sleep disorders, anxiety, depression and learning difficulties can produce overlapping symptoms and need consideration.^[6]

A thorough assessment takes time: reconstructing a childhood history can be difficult, and people may describe the same behavior differently. An objective measurement could offer another perspective. Whether it improves the assessment depends on how the test was validated and whether it answers the clinical question in front of us.

What does a microRNA blood test measure?

MicroRNAs, usually shortened to miRNAs, are small RNA molecules involved in regulating gene expression. Researchers measure several of them and combine the results in statistical or machine-learning models to look for patterns associated with ADHD. They are candidate biomarkers: measurable biological features that might contribute information about a condition.^[1][5]

You may see this marketed as an “ADHD genetic test.” Measuring RNA expression differs from testing inherited DNA sequence variants. The result does not identify a single gene that determines whether someone has ADHD. Nor does it predict a child’s intelligence or future capabilities.

A blood measurement also does not directly measure dopamine in the brain. The commercial test’s current targets, sample preparation, algorithm and interpretation rules should be checked against the laboratory’s documentation. A published research panel is not automatically the specification of a service offered today.

What do the studies show?

An exploratory Taiwanese study in 2018 examined a panel of 13 miRNAs. The training model reported 86.8% sensitivity and 88.9% specificity; 85% of participants in a small blinded testing set were classified correctly. This provided a reason to investigate further.^[4]

The 2022 study used 12 miRNAs in 145 children with ADHD and 83 healthy controls, aged 6–16. Its research model reported 96% sensitivity and 94.2% specificity. Ninety-two patients completed a year of methylphenidate follow-up, with some miRNA changes associated with response. These are promising findings, but they do not establish that one blood sample can select the best medication for a patient.^[1]

A 2025 meta-analysis included 11 pediatric publications. Pooled sensitivity and specificity were both 82%, with an AUC of 0.89. Heterogeneity was substantial (I² = 83%), and patient selection and testing thresholds raised bias concerns. Further standardization and external validation are needed.^[3]

Michelini and colleagues’ 2022 review focuses on treatment biomarkers, including imaging, EEG and genetics. It concluded that the available evidence did not support immediate treatment applications at that time. ^[2]

What does “95% accurate” mean for an individual?

Sensitivity describes the proportion of people with the condition who test positive. Specificity describes the proportion without it who test negative. Neither is the same as the probability that an individual positive result represents ADHD. That probability also depends on the clinical likelihood before testing, the population and the threshold used.

AUC summarizes discrimination across thresholds. An AUC of 0.89 does not mean that every patient has an 89% chance of receiving a correct diagnosis. These general statistical distinctions matter when interpreting a result outside the setting in which a model was developed.

The comparison group matters too. Distinguishing previously diagnosed children from healthy controls does not establish equal performance when distinguishing ADHD from anxiety, insomnia or other causes of inattention. Those overlapping presentations are common questions in outpatient care.

What about children, adolescents and adults?

Children, adolescents and adults may all seek an assessment, but the evidence differs across age groups. The 2022 study involved children aged 6–16, and the 2025 meta-analysis excluded adults. Adults can discuss their interest in blood testing during a consultation.^[1][3]

For children, the fit with the research population matters as well. Existing medication, co-occurring conditions or an age outside the studied range can create interpretation questions that should be discussed before paying for testing.

When might testing be worth discussing?

If you have had an initial assessment and would like an additional biological measurement, it is reasonable to discuss the potential information, cost and uncertainty. Conflicting observer reports or an unclear symptom history can prompt that discussion, but blood testing has not been shown to reliably settle those disagreements. Better information from everyday settings may be more useful.

How does referral for an adjunctive ADHD blood test work?

1. Book an appointment with Dr. Tam. Mention your ADHD concerns and interest in an adjunctive microRNA blood test.
2. Complete an initial clinical assessment. Bring a symptom timeline, examples of impairment, previous reports and medication details. For a child, caregiver and teacher observations are useful.
3. Discuss suitability and cost. Confirm the laboratory’s age, medication and other acceptance criteria, along with the limits of interpretation.
4. Arrange referral and collection. Attend the designated collection location using the referral information and current preparation instructions.
5. Review the report in follow-up. Interpret it alongside the clinical assessment before deciding on next steps.

The laboratory fee is NT$6,800. Registration and consultation fees are separate. This optional self-pay service provides adjunctive information. Collection location, fasting requirements, turnaround time and report delivery arrangements will be confirmed using the current referral instructions. See the fee page for the published price.

What still needs clinical judgment after the report?

The report does not reconstruct childhood, describe behavior in two settings, or explain the effects on work and relationships. Those questions still need a history. Children’s assessments benefit from caregiver and school information; adults can bring old school reports, family recollections and examples of persistent difficulties.

If the test and the clinical history disagree, the next step is to examine the discrepancy and gather information where needed. A positive result alone should not trigger medication, and a negative result should not dismiss longstanding difficulties. If ADHD is diagnosed, treatment is tailored to the person and can include education, environmental changes, behavioral strategies and medication discussions.

Frequently asked questions

Dr. Tam’s perspective

I want an assessment to explain what has been making daily life difficult, and to lead to a workable treatment plan. A laboratory result can contribute information; its value depends on whether it is valid for the person being tested and whether it changes a clinical decision.

Bring examples from school, work and home, a childhood timeline, previous assessments and a complete medication list. We can then discuss whether this optional test is worth its cost and limitations. Assessment and treatment remain available if you decide against blood testing.

References

1. Wang LJ, Kuo HC, Lee SY, et al. MicroRNAs serve as prediction and treatment-response biomarkers of attention-deficit/hyperactivity disorder and promote the differentiation of neuronal cells by repressing the apoptosis pathway. Transl Psychiatry. 2022;12:67. DOI PubMed
2. Michelini G, Norman LJ, Shaw P, Loo SK. Treatment biomarkers for ADHD: Taking stock and moving forward. Transl Psychiatry. 2022;12:444. DOI
3. Zhong X, Yang H, Zhang R, Xie L, Luo R. Diagnostic accuracy of miRNAs in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Front Public Health. 2025;13:1712404. DOI PubMed
4. Wang LJ, et al. Blood-Bourne MicroRNA Biomarker Evaluation in Attention-Deficit/Hyperactivity Disorder of Han Chinese Individuals: An Exploratory Study. Front Psychiatry. 2018;9:227. DOI
5. Martinez B, Peplow PV. MicroRNAs as potential biomarkers for diagnosis of attention deficit hyperactivity disorder. Neural Regen Res. 2024;19(3):557-562. DOI PubMed
6. Centers for Disease Control and Prevention. Diagnosing ADHD. Reviewed July 30, 2026. Accessed October 20, 2026. CDC

Related reading

• ADHD: symptoms, assessment and treatment
• Adult ADHD and procrastination
• ASRS adult ADHD self-screening